If you have worked in India’s pharma industry, you’ll probably have heard about APAC Biotech before this article. The company is the first in India to work on this new exciting branch of cancer therapeutics: Dendritic Cell Therapy. They conducted the first trial in India on Autologous Dendritic Cell Immunotherapy for Refractory Cancer Treatment and were the first to receive …
Bioinformatics from patient recruitment, disease modeling to preventive healthcare
The Commonwealth Science and Industrial Research Organisation (CSIRO) has advanced Australia with a range of inventions and innovations that have had a significant positive impact on the lives of people around the world. Among the various units in CSIRO, the Health and Biosecurity business unit is committed to advancing public health and protecting biosecurity by improving the safety, quality and …
CStone, OBI, Tessa Therapeutics & more join other immunotherapy leaders at Phar-East 2018
In case you missed our email last week, we shared 8 fantastic immunotherapy experts confirmed to speak at Phar-East 2018, Singapore, taking place 28th February to 2nd March. Speaking on their latest work, these distinguished speakers from Asia pharma industry will share their experience, lessons learnt and future plans. First of all, we have Frank Jiang, CEO and founder of CStone. Recently …
5 minutes with Frank Jiang, founder of CStone, a Chinese immunotherapy biotech company
Immunotherapy advancement is a global trend, but it’s also greatly impacting the future of pharma in Asia. To prepare for this week’s feature, we interviewed Dr Frank Jiang, CEO and founder of CStone, a Chinese biotech company focused on addressing the most important patient needs in China and beyond. With immuno-oncology as CStone’s core therapeutic focus, the company strives to lead Chinese …